Shopping Cart
- Remove All
- Your shopping cart is currently empty
GPRC5D Protein, Human, Recombinant, Fluorescent is expressed in HEK293 mammalian cells. The predicted molecular weight is 65.81 kDa and the accession number is Q9NZD1.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
20 μg | $838 | 7-10 days | |
100 μg | $1,670 | 7-10 days | |
500 μg | $5,310 | 7-10 days |
Biological Activity | Immobilized Human GPRC5D-VLP(Full Length) Protein, Fluorescent at 5 μg/mL (100 μL/well) can bind Anti-Human GPRC5D Antibody, Human IgG1the EC50 is 5-60ng/mL. |
Description | GPRC5D Protein, Human, Recombinant, Fluorescent is expressed in HEK293 mammalian cells. The predicted molecular weight is 65.81 kDa and the accession number is Q9NZD1. |
Species | Human |
Expression System | HEK293 Cells |
Tag | GFP |
Accession Number | Q9NZD1 |
Synonyms | GPRC5D |
Construction | A DNA sequence encoding the human GPRC5D (Q9NZD1) (Met1-Val345) was expressed. This protein carries a GFP tag. Predicted N terminal: Met 1 |
Molecular Weight | 65.81 kDa (predicted) |
Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
Formulation | Supplied as sterile 50 mM Hepes, 150 mM NaCl, 10% Trehalose, pH 7.2. |
Stability & Storage | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | Shipping with blue ice. |
Research Background | Orphan G-protein-coupled receptor family C group 5 member D (GPRC5D) has seven transmembrane segments forming the core of the receptor, as well as an intracellular C-tail and an extracellular N-terminal domain. GPRC5D is highly and selectively expressed on the surface of CD138+ multiple myeloma (MM) cells, whereas in normal tissues, a much lower expression is limited to plasma cells and certain hard keratinizing tissues. This makes GPRC5D a promising marker for monitoring tumor load and a target antigen for MM-specific T cell-engaging therapies such as bispecific antibodies and CAR-T cells. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.